| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3084 | 2019 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 1946 | 2017 |
| Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis S Baxi, A Yang, RL Gennarelli, N Khan, Z Wang, L Boyce, D Korenstein Bmj 360, 2018 | 510 | 2018 |
| Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 39 (1), 30, 2021 | 273 | 2021 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR X Ma, L Long, S Moon, BJS Adamson, SS Baxi Medrxiv, 2020.03. 16.20037143, 2020 | 259 | 2020 |
| Causes of death in long‐term survivors of head and neck cancer SS Baxi, LC Pinheiro, SM Patil, DG Pfister, KC Oeffinger, EB Elkin Cancer 120 (10), 1507-1513, 2014 | 232 | 2014 |
| The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform LGT Morris, R Chandramohan, L West, A Zehir, D Chakravarty, DG Pfister, ... JAMA oncology 3 (2), 244-255, 2017 | 216 | 2017 |
| Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers LA Dunn, EJ Sherman, SS Baxi, V Tchekmedyian, RK Grewal, SM Larson, ... The Journal of Clinical Endocrinology & Metabolism 104 (5), 1417-1428, 2019 | 196 | 2019 |
| Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma V Tchekmedyian, EJ Sherman, L Dunn, C Tran, S Baxi, N Katabi, ... Journal of Clinical Oncology 37 (18), 1529, 2019 | 161 | 2019 |
| Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base JR Cracchiolo, SS Baxi, LG Morris, I Ganly, SG Patel, MA Cohen, ... Cancer 122 (10), 1523-1532, 2016 | 154 | 2016 |
| Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus‐associated oropharyngeal cancer KS Jain, AG Sikora, SS Baxi, LGT Morris Cancer 119 (10), 1832-1837, 2013 | 150 | 2013 |
| Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human … N Lee, H Schoder, B Beattie, R Lanning, N Riaz, S McBride, N Katabi, ... International Journal of Radiation Oncology* Biology* Physics 96 (1), 9-17, 2016 | 146 | 2016 |
| Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) MG Fury, S Baxi, R Shen, KW Kelly, BL Lipson, D Carlson, H Stambuk, ... Anticancer research 31 (1), 249-253, 2011 | 101 | 2011 |
| Survivorship, version 2.2017, NCCN clinical practice guidelines in oncology CS Denlinger, T Sanft, KS Baker, S Baxi, G Broderick, ... Journal of the national comprehensive cancer network 15 (9), 1140-1163, 2017 | 97 | 2017 |
| Solid tumor second primary neoplasms: who is at risk, what can we do? KC Oeffinger, SS Baxi, DN Friedman, CS Moskowitz Seminars in oncology 40 (6), 676-689, 2013 | 93 | 2013 |
| A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma AL Ho, L Dunn, EJ Sherman, MG Fury, SS Baxi, R Chandramohan, ... Annals of Oncology 27 (10), 1902-1908, 2016 | 88 | 2016 |
| Survivorship care plans: Is there buy‐in from community oncology providers? T Salz, MS McCabe, EE Onstad, SS Baxi, RL Deming, RA Franco, ... Cancer 120 (5), 722-730, 2014 | 80 | 2014 |
| Treatment‐related toxicities in older adults with head and neck cancer: a population‐based analysis CB O'Neill, SS Baxi, CL Atoria, JP O'Neill, MC Henman, EJ Sherman, ... Cancer 121 (12), 2083-2089, 2015 | 73 | 2015 |
| A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). SM McBride, EJ Sherman, CJ Tsai, SS Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 36 (15_suppl), 6009-6009, 2018 | 70 | 2018 |
| Ten years of progress in head and neck cancers S Baxi, M Fury, I Ganly, S Rao, DG Pfister Journal of the National Comprehensive Cancer Network 10 (7), 806-810, 2012 | 69 | 2012 |
